Evidence map›Paper›PMID 36261811›Full record

SynthesisCardiovascular diabetology2022

The association between macrovascular complications and intensive care admission, invasive mechanical ventilation, and mortality in people with diabetes hospitalized for coronavirus disease-2019 (COVID-19).

Gemma Llauradó, Bogdan Vlacho, Matthieu Wargny, Yue Ruan, Josep Franch-Nadal, Pere Domingo, Pierre Gourdy, Pierre-Jean Saulnier, Samy Hadjadj, Sarah H Wild and 5 more

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in Cardiovascular diabetology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 3 countries.

Gemma Llauradó *Department of Endocrinology and Nutrition, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.
Bogdan Vlacho *DAP_CAT Group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari Per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gorina (IDIAPJGol), Barcelona, Spain.
Matthieu Wargny *L'Institut du Thorax, Université de Nantes, CHU Nantes, CNRS, Nantes, Inserm, France.
Yue Ruan *Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Josep Franch-NadalDepartment of Endocrinology and Nutrition, Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Pere DomingoInfectious Diseases, Hospital de la Santa Creu i Sant Pau and Sant Pau Biomedical Research Institute (IIB Sant Pau), Barcelona, Spain.
Pierre GourdyCHU de Toulouse & UMR1297/I2MC, Inserm, Université de Toulouse, Toulouse, France.
Pierre-Jean SaulnierCentre d'Investigation Clinique CIC 1402, Université de Poitiers, Inserm, CHU de Poitiers, Poitiers, France.
Samy HadjadjL'Institut du Thorax, Université de Nantes, CHU Nantes, CNRS, Nantes, Inserm, France.
Sarah H WildUsher Institute, University of Edinburgh, Edinburgh, UK.
Rustam ReaOxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Bertrand CariouL'Institut du Thorax, Université de Nantes, CHU Nantes, CNRS, Nantes, Inserm, France.
Kamlesh KhuntiDiabetes Research Centre, Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK.
Dídac Mauricio *Department of Endocrinology and Nutrition, Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain. didacmauricio@gmail.com.
CORONADO, the ABCD COVID-19 diabetes national audit, HM Hospitales investigators and the Hospital del Mar - Hospital de la Santa Creu i Sant Pau Diabetes Research Group
Inserm · FRCentre Hospitalier Universitaire de Toulouse · FRInstituto de Salud Carlos III · ESHospital del Mar Research Institute · ESCentre National de la Recherche Scientifique · FRHospital de Sant Pau · ESUniversity of Edinburgh · GBLeicester General Hospital · GBOxford Centre for Diabetes, Endocrinology and Metabolism · GBHôpital Rangueil · FRInstitut de Virologie · FRTranslational Innovation in Medicine and Complexity · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is not clear whether pre-existing macrovascular complications (ischemic heart disease, stroke or peripheral artery disease) are associated with health outcomes in people with diabetes mellitus hospitalized for COVID-19.

methodsWe conducted cohort studies of adults with pre-existing diabetes hospitalized for COVID-19 infection in the UK, France, and Spain during the early phase of the pandemic (between March 2020-October 2020). Logistic regression models adjusted for demographic factors and other comorbidities were used to determine associations between previous macrovascular disease and relevant clinical outcomes: mortality, intensive care unit (ICU) admission and use of invasive mechanical ventilation (IMV) during the hospitalization. Output from individual logistic regression models for each cohort was combined in a meta-analysis.

resultsComplete data were available for 4,106 (60.4%) individuals. Of these, 1,652 (40.2%) had any prior macrovascular disease of whom 28.5% of patients died. Mortality was higher for people with compared to those without previous macrovascular disease (37.7% vs 22.4%). The combined crude odds ratio (OR) for previous macrovascular disease and mortality for all four cohorts was 2.12 (95% CI 1.83-2.45 with an I

conclusionsThis large multinational study of people with diabetes mellitus hospitalized for COVID-19 demonstrates that previous macrovascular disease is associated with higher mortality and lower proportions admitted to ICU and treated with IMV during hospitalization suggesting selective admission criteria. Our findings highlight the importance correctly assess the prognosis and intensive monitoring in this high-risk group of patients and emphasize the need to design specific public health programs aimed to prevent SARS-CoV-2 infection in this subgroup.

Indexed as

COVID-19Diabetes MellitusMyocardial IschemiaAdultCritical CareHospitalizationHumansRespiration, ArtificialRisk FactorsSARS-CoV-2COVID-19DiabetesMacrovascular diseaseMortality

Identifiers

PMID36261811
PMCPMC9580453
OpenAlexW4306846759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.